Biogen Idec 4Q Revenues: $708 million (+12%) 4Q Earnings: $109 million (+95%) FY Revenues: $2.68 billion (+11%) FY Earnings: $218 million (+35%) Comments: Revenues for the quarter and FY2006 included $218 million and $811 million, respectively, from Biogen’s joint business arrangement related to Rituxan. For the quarter, Avonex sales were up 6% to $439 million and for the year were up 11% to $1.7 billion. During 2006 the company launched Rituxan in rheumatoid arthritis ...